Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV



We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.

Lead Researchers

Link to Publication


  1. Jason Brophy

    Investigator, CHEO Research Institute

    View Profile Email